BlueRock Therapeutics Stock

bluerocktx.comHealthcare / BioTech & PharmaFounded: 2016Funding to Date: $225MM

BlueRock Therapeutics is an engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases with a platform that harnesses the power of cells for new medicines across neurology, cardiology and autoimmune indications.

Register To Buy and Sell Shares

For more details on financing and valuation for BlueRock Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access BlueRock Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like BlueRock Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Emile Nuwaysir Ph.D
Chief Executive Officer, President & Board Member
Gordon Keller Ph.D
Scientific Co-Founder
Shane Kovacs
Chief Business and Financial Officer
Min Wang Ph.D
Chief Administrative & Legal Officer
Lorenz Studer Ph.D
Scientific Co-Founder
Robert Deans Ph.D
Chief Technology Officer
Joachim Fruebis Ph.D
Chief Development Officer
Michael Scott Ph.D
Senior Vice President, Product Development

Board Members

Bradley Bolzon Ph.D
Versant Venture Management
Jerel Davis Ph.D
Versant Venture Management
Jurg Eckardt MD
Axel Bouchon

Frequently Asked Questions About BlueRock Therapeutics’ Stock

plusminus
Can you buy BlueRock Therapeutics’ stock?
BlueRock Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy BlueRock Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell BlueRock Therapeutics’ stock?
Yes, you can sell stock of a private company like BlueRock Therapeutics. Forge can help you sell your BlueRock Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is BlueRock Therapeutics’ stock price?
BlueRock Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access BlueRock Therapeutics’ private market stock price with Forge Data.
plusminus
What is BlueRock Therapeutics’ stock ticker symbol?
BlueRock Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Bayer christens $250M cell therapy 'launch facility' in Berkeley
Bayer AG and its subsidiary, BlueRock Therapeutics, have reported positive early-stage results for their experimental Parkinson's disease stem cell therapy, bemdaneprocel. The treatment was well-tolerated in all 12 patients in the phase 1 study and showed potential to reform neural networks and restore motor and non-motor function. Following these results, a phase 2 study is planned for the first half of 2024.
Bayer claims early lead in Parkinson's stem cell therapy
Bayer's subsidiary BlueRock is leading the way in Parkinson's stem cell therapy. In a Phase I trial, BlueRock's therapy was well tolerated and the cells grew as expected in patients' brains. This has prompted the company to progress to the second stage of testing, with patient enrollment expected in the first half of 2024.
Updated on: Feb 25, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.